Grace Therapeutics receives FDA CRL for GTx-104 NDA; schedules Type A meeting
Grace Therapeutics announced it received a Complete Response Letter from the FDA for its GTx-104 new drug application with issues related to manufacturing controls and non-clinical data, but no clinical deficiencies. The company has scheduled a Type A meeting with the FDA to clar
View filing at SEC.gov →